CancerfromTNW | Health-Tech2 days agoUCB pays up to $2.2bn for Candid Therapeutics, doubling down on T-cell engagers in autoimmune diseaseUCB is acquiring Candid Therapeutics for $2bn to advance T-cell engagers for treating autoimmune diseases.